康诺亚公司在 2026 年有哪些重大变化和发展？ 康诺亚公司在 2026 年有几个重要的变化和发展。首先，康悦达（CM310）作 为国内首个用于特应性皮炎的生物制剂，于 2024 年 9 月上市，并于 2025 年 完成了第一个完整销售年度。由于其靶点不仅限于特应性皮炎，还包括慢性鼻 窦炎伴鼻息肉（CRS 伴鼻息肉）和季节性过敏性鼻炎（SAR），这三个适应症 均已纳入 2026 年的医保目录，价格谈判结果也非常理想。 其次，康诺亚的 18.2 ADC 产品是全球首个进入临床的 first-in-class 产品。尽管其靶点并非首 创，但它在市场上具有显著潜力。康诺亚还将 CMG901 授权给阿斯利康，用 于二线胃癌治疗，该产品预计将在 2026 年上半年完成全球注册三期试验并递 交 NDA。此外，该产品还新增了一线适应症，并启动了三期试验。 第三，康 悦达的新型注射笔装置于 2025 年第四季度上市，并同步纳入医保，这将极大 康诺亚 CM310 已获批多项适应症并纳入医保，显著提升市场覆盖率和 销售额，新型注射笔装置进一步提高患者使用便利性，有望带来销售增 量，预计未来峰值有望达到 40-50 亿人民币。 1 ...

每经AI快讯，康诺亚-B(02162.HK)涨近3%，截至发稿，涨2.24%，报57港元，成交额1971.12万港元。 ...

康诺亚-B(02162)涨近3%，截至发稿，涨2.24%，报57港元，成交额1971.12万港元。 消息面上，据康诺亚-B官微消息，近日，康诺亚和合作伙伴Ouro Medicines Ltd共同宣布，BCMA×CD3 双抗CM336(OM336)获美国FDA授予快速通道资格(FTD)认定，用于治疗自身免疫性溶血性贫血(AIHA) 和免疫性血小板减少症(ITP)。CM336在AIHA和ITP两项适应症上获得快速通道资格认定，凸显该类疾 病对创新治疗方案的急迫需求，也再次体现CM336在自身免疫性疾病上的治疗潜力。 此前，康诺亚与Ouro Medicines Ltd订立独家许可协议，授予Ouro Medicines在全球(不包括中国内地、香 港、澳门及台湾地区)研究、开发、生产、注册及商业化CM336的独家权利。CM336已获得FDA授予的 用于治疗AIHA和ITP两项适应症的孤儿药资格认定(ODD)。 ...

智通财经APP获悉，康诺亚-B(02162)涨近3%，截至发稿，涨2.24%，报57港元，成交额1971.12万港 元。 消息面上，据康诺亚-B官微消息，近日，康诺亚和合作伙伴Ouro Medicines Ltd共同宣布，BCMA×CD3 双抗CM336(OM336)获美国FDA授予快速通道资格(FTD)认定， 用于治疗自身免疫性溶血性贫血(AIHA) 和免疫性血小板减少症(ITP)。CM336在AIHA和ITP两项适应症上获得快速通道资格认定，凸显该类疾 病对创新治疗方案的急迫需求，也再次体现CM336在自身免疫性疾病上的治疗潜力。 此前，康诺亚与Ouro Medicines Ltd订立独家许可协议，授予Ouro Medicines在全球(不包括中国内地、香 港、澳门及台湾地区)研究、开发、生产、注册及商业化CM336的独家权利。CM336已获得FDA授予的 用于治疗AIHA和ITP两项适应症的孤儿药资格认定(ODD)。 ...

Group 1 - The core viewpoint is that innovative drugs are expected to show significant excess returns in 2025, driven by continuous BD overseas expansion, excellent clinical data, and policy support [1] - The CXO sector is anticipated to experience substantial growth due to the recovery in demand and improved investment environment in the global pharmaceutical industry [1] - The report emphasizes the importance of focusing on new technologies, particularly bispecific antibodies, small nucleic acid drugs, AI healthcare, and brain-computer interface innovations [3] Group 2 - Domestic supply and demand are relatively stable, with national health expenditure showing a year-on-year growth of 4.7% from January to November 2025, marking a positive turnaround after two years of decline [2] - The medical insurance fund's income and expenditure growth rates continue to decline, with total income of 2.63 trillion yuan (+2.9%) and expenditure of 2.11 trillion yuan (+0.5%) from January to November [2] - The report suggests that the commercialization of new drug forms is entering a critical phase, with significant clinical data supporting the application of B-cell depletion therapies in autoimmune diseases [3] Group 3 - Investment recommendations include focusing on innovative overseas expansion and new technology directions, with suggested stocks such as Mindray Medical, WuXi AppTec, and others [4] - The report highlights the potential for explosive growth in the global market for brain-computer interfaces, supported by policy incentives and technological breakthroughs [3]

Group 1: BYD / Passenger Vehicles - BYD reported a total sales volume of 4.6024 million vehicles in 2025, representing a year-on-year increase of 7.73% despite a monthly sales decline of 18.3% in December 2025 [3][4] - The sales of the high-end model "Fangchengbao" surged by 345.5% year-on-year in December 2025, with annual sales reaching 235,000 units, indicating a strong performance in the high-end market segment [4] - BYD's overseas sales reached 1.0496 million units in 2025, a year-on-year increase of 145%, solidifying its position as the global leader in the new energy vehicle market [4][5] Group 2: Kangnuo Ya-B / Biopharmaceuticals - Kangnuo Ya's innovative biological agent, Kangyueda, has been included in the national medical insurance reimbursement list, enhancing patient accessibility and reducing financial burdens [6][7] - The drug shows significant efficacy in treating moderate to severe atopic dermatitis, with response rates of 92.5% and 77.1% for EASI-75 and EASI-90, respectively [7] - Revenue projections for Kangnuo Ya are estimated at 741 million yuan for 2025, increasing to 1.9 billion yuan by 2027, with a "buy" rating assigned based on the growth potential of its innovative product pipeline [8] Group 3: Lithium Carbonate and Glyphosate Industry - The lithium carbonate price increased by 14.69% week-on-week, reaching 140,500 yuan per ton, driven by strong demand in the energy storage sector [17] - Glyphosate prices rose by 4.78% week-on-week, reflecting a recovery in demand and a tightening supply situation in the market [17][12] - The chemical industry is expected to experience a revaluation due to supply-side changes and a potential shift towards higher dividend yields as capacity expansion slows [12][13] Group 4: Shenli Environment / General Equipment - Shenli Environment is focusing on expanding production capacity and overseas markets, with a significant increase in orders for high-efficiency liquid cooling equipment [36][38] - The company aims to enhance its product delivery capabilities through the establishment of new intelligent production lines, ensuring timely and high-quality order fulfillment [38] - The data service segment is projected to become a core growth driver, with substantial order growth expected in the coming years [40][41] Group 5: Textile and Apparel Industry - The textile manufacturing sector is expected to improve as tariff impacts wane, with a focus on leading manufacturers benefiting from stable operations and improved order flows [43][44] - The domestic sports footwear and apparel market is showing signs of recovery, particularly among high-end brands, with expectations for accelerated growth in 2026 [44] - The luxury goods market in China is gradually recovering, driven by wealth effects and improved retail performance, with a projected growth of approximately 4% in 2026 [45]

Investment Rating - The report indicates a positive investment outlook for the innovative drug sector, particularly focusing on the advancements in T-cell engagers (TCE) for multiple myeloma (MM) treatment [1]. Core Insights - Johnson & Johnson's teclistamab has shown significant efficacy in the treatment of relapsed or refractory multiple myeloma (r/r MM), with a 71% reduction in disease progression or death risk and a 40% reduction in mortality risk compared to standard treatments [14][15]. - The report highlights the unmet medical needs in the MM treatment landscape, emphasizing the potential of TCE therapies targeting BCMA and GPRC5D to improve patient outcomes [9][10]. - The ongoing clinical trials and approvals for various TCE therapies, including teclistamab and talquetamab, are expected to reshape the treatment paradigm for MM, particularly in patients who have undergone multiple lines of therapy [28][34]. Summary by Sections Innovative Drug Focus - The report reviews the recent developments in innovative drugs, particularly in the context of TCE therapies for blood cancers, with a focus on their expanding applications beyond hematological malignancies [5][7]. TCE Therapy Developments - TCE therapies have gained traction in the treatment of MM, with several candidates achieving FDA approval for patients who have received multiple prior therapies. The overall response rates (ORR) for these therapies range from 60% to 74% [9][10]. - The report details the clinical trial results for teclistamab, which has been shown to significantly improve progression-free survival (PFS) and overall survival (OS) in r/r MM patients [14][21]. Market Potential - The report estimates that the sales for teclistamab in China could reach approximately $5.49 billion by 2024, indicating a strong market potential for TCE therapies in the region [6]. - The ongoing research and development efforts in TCE therapies are expected to address the significant unmet needs in the MM treatment landscape, with a focus on improving patient outcomes and survival rates [9][10].

Group 1 - The 2025 Hurun China Unicorn Graduation List identifies 796 companies that have graduated as unicorns, valued at over $1 billion, established after 2000 [1][3] - Chengdu ranks seventh in the number of listed companies, with 18 enterprises making the list [1][4] - The total value of these unicorn graduates across China reaches 24 trillion RMB, with an average establishment year of 2006 and an average age of 19 years [2][3] Group 2 - The top five industries by the number of listed companies are semiconductors, industrial equipment, biotechnology, new energy, and software services, accounting for 46% of the total [3] - The highest valued industries are semiconductors, new energy, industrial equipment, consumer electronics, and biotechnology [3] - Among the 796 unicorn graduates, 33 companies are valued over 100 billion RMB, with 3 exceeding 1 trillion RMB [3][4] Group 3 - Chengdu's notable companies include: - Xinyi Technology (New Easy Win) ranked 44th with a valuation of 82 billion RMB in telecommunications [2][5] - Kelong Botai Biotechnology ranked 55th with a valuation of 11 billion RMB in biotechnology [2][5] - Zhonghang Unmanned Aerial Vehicle ranked 149th with a valuation of 30 billion RMB in robotics [2][5] - Chengdu Huami and Jiachitech both ranked 236th with valuations of 21 billion RMB in semiconductors and new materials respectively [2][5] - Other notable companies include Dekang Agriculture Technology, Huatuo Shanding, and Tea Hundred Road, with valuations ranging from 13 billion to 19 billion RMB [2][5]

Core Insights - The report from China Merchants Securities International indicates that the pharmaceutical industry will experience differentiated growth by 2026, with chronic diseases remaining the largest driver for the future of the pharmaceutical sector [1] - The report emphasizes that upgrades on the supply side and improvements in the operational quality of representative companies are key strategies for bottom-up stock selection [1] - It highlights that the US and China will engage in more competition and collaboration in the innovative drug sector, with policy disruptions causing fluctuations but not altering the long-term development direction of the industry [1] Industry Focus - The report expresses a positive outlook on the biopharmaceutical sector, identifying key companies such as Novartis, Innovent Biologics, Aileron Therapeutics, Hansoh Pharmaceutical, and CanSino Biologics as industry favorites [1] - Additional recommendations include companies like Healer, China Resources Pharmaceutical, Thermo Fisher Scientific, and Eli Lilly [1]

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 康諾亞生物醫藥科技有限公司（於開曼群島註冊成立的有限公司） 呈交日期: 2026年1月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02162 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 500,000,000 | USD | | 0.0001 | USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | | USD | | 0 | | 本月底結存 | | | 500,000,000 | USD | | 0.0001 | USD | ...